Abstract: The present invention relates to a class of melanocortin MCR4 agonists of general formula (I) wherein R1, R2, R3, R4 and R5 are as defined herein and especially to selective MCR4 agonist compounds, to their use in medicine, to compositions containing them, to processes for their preparation and to intermediates used in such processes.

Abstract: The present invention provides for MCHR1 antagonist compounds of formula (I) and the pharmaceutically acceptable salts, solvates and prodrugs thereof, wherein the substituents are as defined herein, and the pharmaceutically acceptable salts, solvates and prodrugs thereof, which are useful in treating diseases or conditions wherein antagonism of the MCHR1 receptor is beneficial.

Abstract: The present invention relates to a class of melanocortin MCR4 agonists of general formula (I) wherein R1, R2, R3, R4 and R5 are as defined herein and especially to selective MCR4 agonist compounds, to their use in medicine, to compositions containing them, to processes for their preparation and to intermediates used in such processes.

Abstract: The present invention relates to compounds of formula (I), wherein R1 is selected from: (a) (C1-C6)alkyl, optionally substituted by 1-3 substituents, each independently selected from: (i) CF3, OH, (C1-C6)alkyl, (C3-C6)cycloalkyl, (C1-C6)alkoxy and halo. (ii) Phenyl, optionally fused with phenyl or cyclohexyl, said phenyl or fused phenyl optionally substituted with 1-3 groups selected from (C1-C6)alkyl, (C1-C6)alkyl ester, OH and halo; and (b) (C3-C6)cycloalkyl, optionally fused with (C5-C7)cycloalkyl, said cycloalkyl or fused cycloalkyl optionally substituted by OH, (C1-C6)alkyl, (C1-C6)alkoxy and halo.

Abstract: Conventional biological processes for treating wastewater include the so-called activated sludge process which is continuous and the sequencing batch reactor (SBR) activated sludge process. The first process requires the use of dedicated, relatively expensive external clarifiers, and the second process is inefficient in terms of treatment volume. A modified sequencing batch reactor process and system enable the efficient, continuous treatment of wastewater, combining the advantages of the SBR and activated sludge processes. Wastewater is treated in three contiguous treatment sections, each of which includes a plurality of contiguous cells. In a first series of operations, the flow direction is from the first to the third sections, and in a second series of operations the flow is reversed. In each series of operations, the first step is to aerobically treat the wastewater, and then allow the sludge to settle before discharging the treated wastewater from the system.